1800-272-662
Shopping Cart 0
countryflagAU
Login

MedMira Inc

Healthcare CA MIR

0.07CAD
0.01(16.67%)

Last update at 2026-03-11T13:30:00Z

Day Range

0.070.07
LowHigh

52 Week Range

0.060.14
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap49.12M
  • Volume100000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.62929M
  • Revenue TTM0.25M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.69518M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Income before tax -4.52441M -3.32632M -2.67566M -1.83157M -0.67580M
Minority interest - - - - -
Net income -4.52441M -3.32632M -2.67566M -1.83158M -0.67580M
Selling general administrative 1.61M 1.48M 0.84M 0.73M 0.49M
Selling and marketing expenses - - 0.20M 0.01M 0.04M
Gross profit 0.17M 0.23M 0.30M 0.30M 1.72M
Reconciled depreciation 0.32M 0.31M 0.21M 0.21M 0.21M
Ebit - - -1.79014M -1.27954M -0.02250M
Ebitda - - -1.57724M -1.06724M 0.19M
Depreciation and amortization - - 0.21M 0.21M 0.21M
Non operating income net other - - - - -
Operating income -3.44885M -2.42991M -1.94432M -1.45322M -0.18423M
Other operating expenses - - 2.21M 2.22M 2.14M
Interest expense 1.08M 0.88M 0.89M 0.55M 0.65M
Tax provision - - - - -
Interest income - - - - -
Net interest income -1.07555M -0.89641M -0.89752M -0.56203M -0.68169M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.15M 0.17M 0.16M
Total revenue 0.24M 0.41M 0.43M 0.95M 2.14M
Total operating expenses 3.69M 2.84M 2.08M 1.57M 1.72M
Cost of revenue 0.07M 0.19M 0.13M 0.65M 0.42M
Total other income expense net - - -0.73134M -0.37835M -0.49156M
Discontinued operations - - - - -
Net income from continuing ops -4.52441M -3.32632M -2.67566M -1.83157M -0.67580M
Net income applicable to common shares - - - -1.83158M -0.67580M
Preferred stock and other adjustments - - - - -
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total assets 3.68M 6.07M 3.65M 3.83M 3.89M
Intangible assets 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Earning assets - - - - -
Other current assets - - - - -
Total liab 26.24M 24.11M 18.68M 16.19M 19.61M
Total stockholder equity -22.56101M -18.03661M -15.03166M -12.35600M -15.72390M
Deferred long term liab - - - - -
Other current liab 0.00000M 0.00000M - 0.61M 1.23M
Common stock - - - 68.35M 63.90M
Capital stock 68.67M 68.67M 68.35M 68.35M 63.90M
Retained earnings -105.80983M -101.28542M -97.95910M -95.28345M -93.45187M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.01M 2.10M 0.01M 0.03M -
Cash and equivalents - - - - -
Total current liabilities 22.02M 20.95M 15.73M 14.14M 17.41M
Current deferred revenue - - - - -
Net debt 8.30M 4.90M 7.25M 6.11M 9.23M
Short term debt - - - - -
Short long term debt 6.30M 6.11M 6.14M 6.10M 9.19M
Short long term debt total - - - - -
Other stockholder equity - - - 14.58M 13.82M
Property plant equipment - - - 2.17M 2.31M
Total current assets 1.60M 3.68M 1.69M 1.66M 1.58M
Long term investments - - - - -
Net tangible assets - - - -12.35850M -15.72640M
Short term investments - - - - -
Net receivables 1.32M 1.33M 1.26M 1.37M 1.25M
Long term debt 2.01M 0.89M 1.12M 0.04M 0.04M
Inventory 0.21M 0.18M 0.18M 0.20M 0.24M
Accounts payable 2.91M 2.72M 3.26M 2.75M 2.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 2.08M 2.39M 1.96M 2.17M 2.31M
Capital lease obligations 2.39M 2.56M 2.01M 2.16M 2.30M
Long term debt total - - - - -
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Investments - -0.74253M -0.00127M -0.06972M -0.03655M
Change to liabilities - - - -0.57187M 0.32M
Total cashflows from investing activities - - - -0.06972M -0.03655M
Net borrowings 1.02M 0.55M - 0.35M -0.37493M
Total cash from financing activities 1.07M 5.77M 1.25M 1.99M 0.14M
Change to operating activities - - - 0.39M 0.70M
Net income -4.52441M -3.32632M -2.67566M -1.83158M -0.67580M
Change in cash -2.08269M 2.08M -0.02028M 0.03M -0.40186M
Begin period cash flow 2.10M 0.01M 0.03M 0.00000M 0.40M
End period cash flow 0.01M 2.10M 0.01M 0.03M 0.00000M
Total cash from operating activities -3.14546M -2.93852M -1.26775M -1.88396M -0.50464M
Issuance of capital stock - - 0.00000M 1.67M 0.52M
Depreciation 0.32M 0.31M 0.21M 0.21M 0.21M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.02804M 0.00439M 0.02M 0.03M -0.01319M
Change to account receivables 0.01M -0.07064M -0.01117M 0.00056M -1.04286M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - 1.40M 0.53M 0.06M
Change to netincome - - - - -
Capital expenditures 0.00747M 0.74M 0.00127M 0.07M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.94M 0.03M 1.20M -0.26467M -0.03664M
Stock based compensation - - - - -
Other non cash items - 0.02M -0.04849M 0.46M 1.09M
Free cash flow -3.15293M -3.68106M -1.26902M -1.95367M -0.54119M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MIR
MedMira Inc		 0.01 16.67% 0.07 - - 180.71 - 236.85 -80.0318
NGEN
NervGen Pharma Corp		 -0.05 0.91% 5.45 - - - 189.48 -4.5367
SHRX
Sharp Therapeutics Corp.		 - -% 2.25 - - - 37.28
ARCH
Arch Biopartners Inc		 -0.03 3.95% 0.73 - - 196.47 - 53.05 -97.5918
NRX
NurExone Biologic Inc.		 -0.02 3.33% 0.58 - 6.90 - 31.03 -7.2365

Reports Covered

Stock Research & News

View All

Profile

MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.

MedMira Inc

155 Chain Lake Drive, Halifax, NS, Canada, B3S 1B3

Key Executives

Name Title Year Born
Mr. Hermes Chan Co-Founder, CEO, Pres & Director NA
Mr. Markus M. Meile Chief Financial Officer NA
Stewart McKelvey Legal Counsel NA
Dr. Kevin D. Jones Head of Commercialization and Sr. Director of Sales & Marketing 1969
Mr. Hermes Chan Co-Founder, CEO, President & Director NA
Dr. Sam Ratnam Director of Scientific & Regulatory Affairs NA
Dr. Kevin D. Jones Head of Commercialization and Senior Director of Sales & Marketing 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.